Parvovirus B19 is an icosahedral virus with a single-stranded, linear DNA genome. This virus exclusively affects humans. It is known that this virus causes fifth illness, also known as slapped cheek syndrome or erythema infectiosum, which primarily affects young children but can potentially affect adults.
In addition, it can cause aplastic crises in individuals who are affected with some forms of anemia; polyarthropathy, papular purpuric glove and socks syndrome in young individuals; and hydrops fetalis in pregnant women. The virus is transmitted through blood and respiratory secretions. An infected pregnant women can transmit this illness to the child.
Epidemiology
Infection with Parvovirus B19 is widespread and particularly prevalent among school-aged children.
In affluent countries, the prevalence of parvovirus B19 in children below the age of 5 is between 2%-10%, 40%-60% in individuals over the age of 20, and 85% or higher in those older than 70 years.
Parvovirus B19 infections are more prevalent in early spring, early summer and late winter. Every 3-4 years, small outbreaks of the parvovirus B19 occur.
Anatomy
Pathophysiology
Parvovirus B19 enters the respiratory tract after binding to the receptors found on host cells. It subsequently translocates its genome into the nucleus of the host, where processes such as DNA replication, RNA transcription, and virus assembly occur.
The cells then lyse and release mature virions. Patients develop a predrome of symptoms as a result of viremia. When the viremia settles — approximately eight to ten days post-inoculation, the IgM antibody is found.
7-10 days of reticulocytopenia occur during the viremic phase. IgG antibodies occur one week following IgM antibodies, accompanied by a rash and arthralgia.
Parvovirus is endemic to bone marrow and replicates in progenitors to erythroid cells. The cellular receptor for the parvovirus B19 is the P-anitgen, and it causes erythema infectiosum in children.
Etiology
The paravirus B19 is an icosahedral, non-enveloped virus with a single-stranded linear DNA molecule. As the virus can only infect humans, there’s no animal to human transmission.
Genetics
Prognostic Factors
Erythema infectiosum is typically moderate in healthy individuals. Although it may cause severe complications in immunocompromised individuals.
Some patients may develop chronic anemia on infection. After contracting erythema infectiosum, the individual develops permanent immunity from this illness.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK482245/
News
Female Surgeons in NHS Face Rampant Sexual Harassment
Posted on
News
Gene Therapy Promises Restoration of Motor Function
Posted on
News
Ultra-Processed Foods Linked to Elevated Depression Risk in Women
Posted on
News
Research Reveals How Language Shapes Social Memory in the Brain
Parvovirus B19 is an icosahedral virus with a single-stranded, linear DNA genome. This virus exclusively affects humans. It is known that this virus causes fifth illness, also known as slapped cheek syndrome or erythema infectiosum, which primarily affects young children but can potentially affect adults.
In addition, it can cause aplastic crises in individuals who are affected with some forms of anemia; polyarthropathy, papular purpuric glove and socks syndrome in young individuals; and hydrops fetalis in pregnant women. The virus is transmitted through blood and respiratory secretions. An infected pregnant women can transmit this illness to the child.
Infection with Parvovirus B19 is widespread and particularly prevalent among school-aged children.
In affluent countries, the prevalence of parvovirus B19 in children below the age of 5 is between 2%-10%, 40%-60% in individuals over the age of 20, and 85% or higher in those older than 70 years.
Parvovirus B19 infections are more prevalent in early spring, early summer and late winter. Every 3-4 years, small outbreaks of the parvovirus B19 occur.
Parvovirus B19 enters the respiratory tract after binding to the receptors found on host cells. It subsequently translocates its genome into the nucleus of the host, where processes such as DNA replication, RNA transcription, and virus assembly occur.
The cells then lyse and release mature virions. Patients develop a predrome of symptoms as a result of viremia. When the viremia settles — approximately eight to ten days post-inoculation, the IgM antibody is found.
7-10 days of reticulocytopenia occur during the viremic phase. IgG antibodies occur one week following IgM antibodies, accompanied by a rash and arthralgia.
Parvovirus is endemic to bone marrow and replicates in progenitors to erythroid cells. The cellular receptor for the parvovirus B19 is the P-anitgen, and it causes erythema infectiosum in children.
The paravirus B19 is an icosahedral, non-enveloped virus with a single-stranded linear DNA molecule. As the virus can only infect humans, there’s no animal to human transmission.
Erythema infectiosum is typically moderate in healthy individuals. Although it may cause severe complications in immunocompromised individuals.
Some patients may develop chronic anemia on infection. After contracting erythema infectiosum, the individual develops permanent immunity from this illness.
https://www.ncbi.nlm.nih.gov/books/NBK482245/
medtigo
Parvovirus B19
Updated :
July 4, 2022
Parvovirus B19 is an icosahedral virus with a single-stranded, linear DNA genome. This virus exclusively affects humans. It is known that this virus causes fifth illness, also known as slapped cheek syndrome or erythema infectiosum, which primarily affects young children but can potentially affect adults.
In addition, it can cause aplastic crises in individuals who are affected with some forms of anemia; polyarthropathy, papular purpuric glove and socks syndrome in young individuals; and hydrops fetalis in pregnant women. The virus is transmitted through blood and respiratory secretions. An infected pregnant women can transmit this illness to the child.
Infection with Parvovirus B19 is widespread and particularly prevalent among school-aged children.
In affluent countries, the prevalence of parvovirus B19 in children below the age of 5 is between 2%-10%, 40%-60% in individuals over the age of 20, and 85% or higher in those older than 70 years.
Parvovirus B19 infections are more prevalent in early spring, early summer and late winter. Every 3-4 years, small outbreaks of the parvovirus B19 occur.
Parvovirus B19 enters the respiratory tract after binding to the receptors found on host cells. It subsequently translocates its genome into the nucleus of the host, where processes such as DNA replication, RNA transcription, and virus assembly occur.
The cells then lyse and release mature virions. Patients develop a predrome of symptoms as a result of viremia. When the viremia settles — approximately eight to ten days post-inoculation, the IgM antibody is found.
7-10 days of reticulocytopenia occur during the viremic phase. IgG antibodies occur one week following IgM antibodies, accompanied by a rash and arthralgia.
Parvovirus is endemic to bone marrow and replicates in progenitors to erythroid cells. The cellular receptor for the parvovirus B19 is the P-anitgen, and it causes erythema infectiosum in children.
The paravirus B19 is an icosahedral, non-enveloped virus with a single-stranded linear DNA molecule. As the virus can only infect humans, there’s no animal to human transmission.
Erythema infectiosum is typically moderate in healthy individuals. Although it may cause severe complications in immunocompromised individuals.
Some patients may develop chronic anemia on infection. After contracting erythema infectiosum, the individual develops permanent immunity from this illness.
https://www.ncbi.nlm.nih.gov/books/NBK482245/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
